SNC-103 is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis). According to GlobalData, Phase I drugs for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SNC-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SNC-103 overview

SNC-103 is under development for the treatment of relapsed or refractory CD19 positive B-cell hematological malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma, diffuse large B lymphoma, primary mediastinal (thymic) large B-cell lymphoma, follicular lymphoma, systemic lupus erythematosus, relapse or refractory antineutrophil cytoplasmic antibody associated vasculitis, refractory idiopathic inflammatory myopathies and relapsed/refractory active diffuse cutaneous systemic sclerosis. The therapeutic candidate (CAR-NK) comprises cord blood derived NK cells genetically engineered to express chimeric antigen receptor (CAR) targeting cells expressing CD19. It is administered through intravenous drip route. 

Shanghai Simnova Biotechnology overview

Shanghai Simnova Biotechnology is a clinical cell therapy platform company. It is headquartered in Shanghai, China.

For a complete picture of SNC-103’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.